{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T02:30:55Z","timestamp":1755225055250,"version":"3.43.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"DOI":"10.7759\/cureus.89937","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T02:53:32Z","timestamp":1755053612000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Outcomes of Antiangiogenic Therapy in Patients With Wet Age-Related Macular Degeneration"],"prefix":"10.7759","author":[{"given":"Diana Laura","family":"Solano Pineda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Italia","family":"Mar\u00edn Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"G\u00f3mez Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolfo","family":"Nu\u00f1ez Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanesa","family":"Flores Peredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erandi","family":"Gonz\u00e1lez Rubio Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Medina Quero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Antonio","family":"Vargas Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Escalera Arroyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell P","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018, 392:1147-59. 10.1016\/S0140-6736(18)31550-2","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review","volume":"331","author":"Fleckenstein M","year":"2024","unstructured":"Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA. 2024, 331:147-57. 10.1001\/jama.2023.26074","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014645","article-title":"Protocol of global incidence and progression of age-related macular degeneration: a systematic review","volume":"98","author":"Zhao S","year":"2019","unstructured":"Zhao S, Lan X, Wu J, et al.. Protocol of global incidence and progression of age-related macular degeneration: a systematic review. Medicine (Baltimore). 2019, 98:e14645. 10.1097\/MD.0000000000014645","journal-title":"Medicine (Baltimore)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000520171","article-title":"Development of macular atrophy in patients with wet age-related macular degeneration receiving anti-VEGF treatment","volume":"245","author":"Foss A","year":"2022","unstructured":"Foss A, Rotsos T, Empeslidis T, Chong V. Development of macular atrophy in patients with wet age-related macular degeneration receiving anti-VEGF treatment. Ophthalmologica. 2022, 245:204-17. 10.1159\/000520171","journal-title":"Ophthalmologica"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)","volume":"98","author":"Schmidt-Erfurth U","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, et al.. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014, 98:1144-67. 10.1136\/bjophthalmol-2014-305702","journal-title":"Br J Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1991.01080090044025","article-title":"Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial","volume":"109","year":"1991","unstructured":"Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol. 1991, 109.1220-31. 10.1001\/archopht.1991.01080090044025","journal-title":"Arch Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.117.10.1329","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age\u2011related macular degeneration with verteporfin: one\u2011year results of 2 randomized clinical trials\u2014TAP report 1","volume":"117","author":"Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group","year":"1999","unstructured":"Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age\u2011related macular degeneration with verteporfin: one\u2011year results of 2 randomized clinical trials\u2014TAP report 1. Arch Ophthalmol. 1999, 117:1329-45. 10.1001\/archopht.117.10.1329","journal-title":"Arch Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.12.002","article-title":"Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors","volume":"65","author":"Mehta H","year":"2018","unstructured":"Mehta H, Tufail A, Daien V, et al.. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res. 2018, 65:127-46. 10.1016\/j.preteyeres.2017.12.002","journal-title":"Prog Retin Eye Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.4948","article-title":"Correlation of 3-dimensionally quantified intraretinal and subretinal fluid with visual acuity in neovascular age-related macular degeneration","volume":"134","author":"Waldstein SM","year":"2016","unstructured":"Waldstein SM, Philip AM, Leitner R, Simader C, Langs G, Gerendas BS, Schmidt-Erfurth U. Correlation of 3-dimensionally quantified intraretinal and subretinal fluid with visual acuity in neovascular age-related macular degeneration. JAMA Ophthalmol. 2016, 134:182-90. 10.1001\/jamaophthalmol.2015.4948","journal-title":"JAMA Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study","volume":"148","author":"Lalwani GA","year":"2009","unstructured":"Lalwani GA, Rosenfeld PJ, Fung AE, et al.. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009, 148:43-58.e1. 10.1016\/j.ajo.2009.01.024","journal-title":"Am J Ophthalmol"},{"key":"ref11","article-title":"Treatment of exudative age-related macular degeneration with anti-angiogenic drugs: analysis of long-term visual function in routine clinical practice","volume":"94","author":"Palaz\u00f3n\u2011Cabanes A","year":"2020","unstructured":"Palaz\u00f3n\u2011Cabanes A, Palaz\u00f3n\u2011Cabanes B, Sell\u00e9s\u2011Navarro I. Treatment of exudative age-related macular degeneration with anti-angiogenic drugs: analysis of long-term visual function in routine clinical practice. Rev Mex Oftalmol. 2020, 94:192-8.","journal-title":"Rev Mex Oftalmol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier JS","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, et al.. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012, 119:2537-48. 10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld PJ","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006, 355:1419-31. 10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown DM","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, et al.. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006, 355:1432-44. 10.1056\/NEJMoa062655","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2020.04.011","article-title":"Visual acuity variability: comparing discrepancies between Snellen and ETDRS measurements among subjects entering prospective trials","volume":"5","author":"Yu HJ","year":"2021","unstructured":"Yu HJ, Kaiser PK, Zamora D, et al.. Visual acuity variability: comparing discrepancies between Snellen and ETDRS measurements among subjects entering prospective trials. Ophthalmol Retina. 2021, 5:224-33. 10.1016\/j.oret.2020.04.011","journal-title":"Ophthalmol Retina"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/397167-real-world-outcomes-of-antiangiogenic-therapy-in-patients-with-wet-age-related-macular-degeneration","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T02:53:34Z","timestamp":1755053614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/397167-real-world-outcomes-of-antiangiogenic-therapy-in-patients-with-wet-age-related-macular-degeneration"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.89937","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}